[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538164":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":153,"collaborators":10,"id":155,"slug":10,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":10,"eligibilityCriteria":160,"healthyVolunteers":156,"sex":161,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":10,"studyType":167,"phases":10,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"eltrombopag",null,"ATG treatment naïve pediatric patients with AA in routine clinical practice",[13],"Other: eltrombopag",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.",[9],[20],{"name":21,"affiliation":21,"role":22},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+81337978748","novartis.email@novartis.com",{"name":21,"role":25,"phone":10,"phoneExt":10,"email":10},[30,43,48,56,64,73,81,90,94,103,110,118,126,130,134,142,145],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Novartis Investigative Site","RECRUITING","Nagoya","Aichi-ken","453-8511","Japan",{"type":38,"coordinates":39},"Point",[40,41],136.90641,35.18147,{"lat":41,"lon":40},{"facility":31,"status":32,"city":33,"state":34,"zip":44,"country":36,"cosmosGeoPoint":45,"geoPoint":47,"contacts":10},"4668560",{"type":38,"coordinates":46},[40,41],{"lat":41,"lon":40},{"facility":31,"status":32,"city":49,"state":34,"zip":50,"country":36,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Toyoake","4701192",{"type":38,"coordinates":52},[53,54],136.99931,35.038,{"lat":54,"lon":53},{"facility":31,"status":32,"city":57,"state":57,"zip":58,"country":36,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"Chiba","260 8677",{"type":38,"coordinates":60},[61,62],140.11667,35.6,{"lat":62,"lon":61},{"facility":31,"status":32,"city":65,"state":66,"zip":67,"country":36,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"Amagasaki","Hyōgo","660 8550",{"type":38,"coordinates":69},[70,71],135.41667,34.71667,{"lat":71,"lon":70},{"facility":31,"status":32,"city":74,"state":66,"zip":75,"country":36,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Kobe","6500047",{"type":38,"coordinates":77},[78,79],135.183,34.6913,{"lat":79,"lon":78},{"facility":31,"status":32,"city":82,"state":83,"zip":84,"country":36,"cosmosGeoPoint":85,"geoPoint":89,"contacts":10},"Matsumoto","Nagano","3908621",{"type":38,"coordinates":86},[87,88],137.96667,36.23333,{"lat":88,"lon":87},{"facility":31,"status":32,"city":91,"state":92,"zip":93,"country":36,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Shimajiri-Gun","Okinawa","901-1303",{"facility":31,"status":32,"city":95,"state":96,"zip":97,"country":36,"cosmosGeoPoint":98,"geoPoint":102,"contacts":10},"Izumi","Osaka","5941101",{"type":38,"coordinates":99},[100,101],135.43333,34.48333,{"lat":101,"lon":100},{"facility":31,"status":32,"city":96,"state":96,"zip":104,"country":36,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"5340021",{"type":38,"coordinates":106},[107,108],135.50107,34.69379,{"lat":108,"lon":107},{"facility":31,"status":32,"city":111,"state":96,"zip":112,"country":36,"cosmosGeoPoint":113,"geoPoint":117,"contacts":10},"Sakai","590-0197",{"type":38,"coordinates":114},[115,116],135.46653,34.58216,{"lat":116,"lon":115},{"facility":31,"status":32,"city":119,"state":119,"zip":120,"country":36,"cosmosGeoPoint":121,"geoPoint":125,"contacts":10},"Saitama","3308777",{"type":38,"coordinates":122},[123,124],139.65657,35.90807,{"lat":124,"lon":123},{"facility":31,"status":32,"city":127,"state":128,"zip":129,"country":36,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Ohtsu","Shiga","5202192",{"facility":31,"status":32,"city":131,"state":132,"zip":133,"country":36,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Chuo Ku","Tokyo","1048560",{"facility":31,"status":32,"city":135,"state":132,"zip":136,"country":36,"cosmosGeoPoint":137,"geoPoint":141,"contacts":10},"Ōta-ku","143 8541",{"type":38,"coordinates":138},[139,140],139.71605,35.56126,{"lat":140,"lon":139},{"facility":31,"status":32,"city":143,"state":132,"zip":144,"country":36,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Setagaya-ku","1578535",{"facility":31,"status":32,"city":146,"state":146,"zip":147,"country":36,"cosmosGeoPoint":148,"geoPoint":152,"contacts":10},"Wakayama","641-8510",{"type":38,"coordinates":149},[150,151],135.16667,34.23333,{"lat":151,"lon":150},{"type":154,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100538164",false,"NCT06287268","Revolade Tablets Specified Drug-use Survey","Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)","Inclusion Criteria:\n\n* Patients whose legally acceptable representative has given written consent for cooperation in this survey prior to enrollment in this survey\n* Patients aged ≥ 6 years and \\\u003C 18 years at the start of treatment with eltrombopag\n* Pediatric patients with AA who receive eltrombopag for the first time in combination with ATG after the approval of additional dosage and administration for \"ATG-naïve pediatric patients with AA\"\n\nExclusion Criteria:\n\n* Patients who have received ATG without concomitant use of eltrombopag\n* Patients with congenital AA\n* Patients with suspected or confirmed diagnosis of myelodysplastic syndrome (MDS) at the start of treatment with eltrombopag\n* Patients who have received any drug products containing the same ingredient as eltrombopag (including investigational products)","ALL","6 Years","17 Years",{"count":165,"type":166},10,"ESTIMATED","OBSERVATIONAL","This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).",[170],"Aplastic Anemia",[172,173,174,175,9,176],"NIS","Pediatric Aplastic Anemia","AA","Revolade Tablets","Drug-use Survey","2026-02-18",{"date":179,"type":180},"2026-02-19","ACTUAL",{"date":182,"type":180},"2024-07-17",{"date":184,"type":166},"2028-10-31",{"name":21,"class":6},17]